Security Snapshot

Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) Institutional Ownership

CUSIP: 761330109

13F Institutional Holders and Ownership History from Q1 2014 to Q4 2025

Latest Period

Q4 2025

Institutions Reporting

0

Shares (Excl. Options)

0

Price

$3.65

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Create free account and return here Sign in and return here Review latest holder period
Type / Class
Equity / Common Stock, par value $0.001 per share
Symbol
RVNC
Shares outstanding
104,661,494
Price per share
$3.65
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
0
Total reported value
$0
Share change
-173,355
Value change
-$899,713
Number of holders
0
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Quick Takeaways

  • RVNC - Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share is tracked under CUSIP 761330109.
  • 0 institutions reported positions in Q4 2025.
  • 3 significant owners is listed from Schedule 13D/13G reporting.

What Changed

  • Holder count moved from 1 to 0 between Q3 2025 and Q4 2025.
  • Reported value moved from $899,713 to $0.

Why This Matters

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Source Evidence

Source: SEC Form 13F

Latest holder context comes from 0 institutions filings for Q4 2025.

Open SEC Evidence

Investment Quick Answers

What is CUSIP 761330109?
CUSIP 761330109 identifies RVNC - Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share in SEC 13F datasets.

Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.

Significant Owners of Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Teoxane SA 6.2% 0% $32,335,404 6,550,800 0% Teoxane SA 30 Jan 2025
FRANKLIN RESOURCES INC 4.6% $23,617,550 4,784,658 Franklin Resources, Inc. 30 Sep 2024
Palo Alto Investors LP 1.5% $7,955,942 1,611,787 Patrick Lee, MD 30 Sep 2024

Institutional Holders of Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 0 $0 -$899,713 $3.65 0
2025 Q3 173,355 $899,713 +$899,713 $5.19 1
2025 Q2 0 $0 -$425,556 $3.65 0
2025 Q1 86,100 $425,000 -$246,196,147 $4.94 1
2024 Q4 81,619,644 $248,123,678 -$34,475,559 $3.04 169
2024 Q3 82,760,696 $429,420,057 +$74,534,872 $5.19 197
2024 Q2 81,357,406 $209,091,543 -$16,845,100 $2.57 167
2024 Q1 83,208,743 $409,387,692 +$36,028,524 $4.92 182
2023 Q4 72,393,492 $636,347,111 -$60,448,695 $8.79 188
2023 Q3 77,847,333 $892,932,350 -$137,486,235 $11.47 184
2023 Q2 81,758,941 $2,069,347,401 +$120,257,967 $25.31 211
2023 Q1 76,516,583 $2,464,233,089 +$117,647,825 $32.21 215
2022 Q4 73,838,140 $1,363,055,604 +$97,419,982 $18.46 189
2022 Q3 67,635,567 $1,824,203,436 +$329,402,349 $27.00 178
2022 Q2 56,025,691 $774,315,063 +$10,576,060 $13.82 156
2022 Q1 54,547,989 $1,063,491,136 +$29,861,073 $19.50 149
2021 Q4 52,976,629 $864,638,987 -$84,608,748 $16.32 143
2021 Q3 54,870,424 $1,528,696,909 +$20,536,734 $27.86 155
2021 Q2 54,097,996 $1,601,222,557 -$17,874,204 $29.64 159
2021 Q1 54,835,912 $1,532,629,456 +$56,326,804 $27.95 148
2020 Q4 52,750,406 $1,494,882,254 +$97,410,291 $28.34 150
2020 Q3 49,472,050 $1,246,067,821 -$26,647,818 $25.14 151
2020 Q2 50,606,433 $1,234,538,861 +$33,125,299 $24.42 138
2020 Q1 49,442,358 $731,960,359 -$26,411,053 $14.80 126
2019 Q4 51,033,735 $828,265,787 +$132,605,351 $16.23 130
2019 Q3 42,640,327 $554,389,602 -$12,035,697 $13.00 106
2019 Q2 43,555,026 $564,029,588 +$26,762,019 $12.97 110
2019 Q1 41,642,925 $656,297,834 +$99,780,800 $15.76 108
2018 Q4 31,877,280 $641,628,318 +$12,346,028 $20.13 97
2018 Q3 34,359,383 $853,830,934 -$15,526,982 $24.85 108
2018 Q2 34,870,390 $957,229,930 +$13,863,223 $27.45 109
2018 Q1 34,209,499 $1,053,625,660 -$35,231,819 $30.80 118
2017 Q4 34,965,934 $1,250,026,502 +$169,498,952 $35.75 115
2017 Q3 27,433,692 $754,721,335 -$1,638,080 $27.55 84
2017 Q2 27,519,844 $726,508,386 +$33,694,307 $26.40 84
2017 Q1 26,264,507 $546,296,202 +$45,342,975 $20.80 76
2016 Q4 26,097,588 $540,211,722 +$12,064,735 $20.70 80
2016 Q3 28,646,674 $464,359,406 -$1,083,385 $16.21 74
2016 Q2 28,779,485 $391,398,386 +$16,844,693 $13.60 79
2016 Q1 27,202,736 $474,936,380 -$25,989,904 $17.46 83
2015 Q4 27,209,685 $929,575,673 +$189,567,566 $34.16 101
2015 Q3 21,644,614 $644,108,702 +$34,896,748 $29.76 76
2015 Q2 20,482,234 $655,028,876 +$16,033,415 $31.98 88
2015 Q1 20,573,529 $426,461,171 +$18,511,994 $20.73 70
2014 Q4 19,758,262 $334,697,612 +$8,318,779 $16.94 68
2014 Q3 15,656,921 $302,653,761 -$45,140,381 $19.33 80
2014 Q2 16,360,522 $556,147,916 +$154,810,773 $34.00 98
2014 Q1 11,832,924 $372,736,175 +$372,736,179 $31.50 65
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .